Search
ALX Oncology Holdings Inc
ALXOAdd to Watchlist
2.070USD
+0.010+0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
278.50MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.49%
5 Days
+1.47%
1 Month
+32.69%
6 Months
+80.00%
Year to Date
+83.19%
1 Year
+349.90%
Key Figures
2.080Open
2.125High
1.07MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.79%Turnover Ratio
2.060Prev. Close
2.015Low
1.37MTurnover
LossP/E Static
1.84P/B
0.00%Div Yield TTM
-59.40%ROA
2.66052wk High
0.45Volume Ratio
-134.85MNet Profit
134.54MShares
-1.4903EPS TTM
0.44Beta
-74.17%ROE
0.40452wk Low
5.34%Amplitude
--Gross Margin
278.50MMarket Cap
4.58Reward/Risk
7.00%Risk Rate
TradingKey Stock Score of ALX Oncology Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
ALX Oncology Holdings Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 167 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.60.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ALX Oncology Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
ALX Oncology Holdings Inc Highlights
StrengthsRisks
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Fairly Valued
The company’s latest PE is -1.39, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.67M shares, decreasing 7.07% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 42.04K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.25.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
4.600
Target Price
+123.30%
Upside Space
ALX Oncology Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ALX Oncology Holdings Inc Info
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Ticker SymbolALXO
CompanyALX Oncology Holdings Inc
CEOLettmann (Jason)
Websitehttps://alxoncology.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of ALX Oncology Holdings Inc (ALXO)?
The current price of ALX Oncology Holdings Inc (ALXO) is 2.07.
What is the symbol of ALX Oncology Holdings Inc?
The ticker symbol of ALX Oncology Holdings Inc is ALXO.
What is the 52-week high of ALX Oncology Holdings Inc?
The 52-week high of ALX Oncology Holdings Inc is 2.66.
What is the 52-week low of ALX Oncology Holdings Inc?
The 52-week low of ALX Oncology Holdings Inc is 0.40.
What is the market capitalization of ALX Oncology Holdings Inc?
The market capitalization of ALX Oncology Holdings Inc is 278.50M.
Is ALX Oncology Holdings Inc (ALXO) currently rated as Buy, Hold, or Sell?
According to analysts, ALX Oncology Holdings Inc (ALXO) has an overall rating of Buy, with a price target of 4.60.
What is the Earnings Per Share (EPS TTM) of ALX Oncology Holdings Inc (ALXO)?
The Earnings Per Share (EPS TTM) of ALX Oncology Holdings Inc (ALXO) is -1.90.